Male and female scientists wearing blue jumpsuits, purple gloves, and goggles look at beaker of liquid in lab

Showcasing New Data at the American Diabetes Association's 83rd Scientific Sessions

New findings presented at the American Diabetes Association’s (ADA) 83rd Scientific Sessions reinforce our commitment to providing breakthrough outcomes across the spectrum of care for diabetes and obesity.

LILLY PRESS RELEASES:
Lilly to present new research in the treatment of diabetes and obesity at the American Diabetes Association’s® 83rd Scientific Sessions
Lilly's phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight
Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes *Tirzepatide is not approved for the treatment of weight loss. Mounjaro (tirzepatide) is an FDA-approved treatment for adults with type 2 diabetes to improve glycemic control used along with diet and exercise. Mounjaro is not a weight loss drug.
Lilly’s phase 2 retatrutide results published in The New England Journal of Medicine show the investigational molecule achieved up to 17.5% mean weight reduction at 24 weeks in adults with obesity and overweight

ADDITIONAL CONTENT FOR DOWNLOAD OR REFERENCE:

Learn more about Lilly’s work in diabetes and obesity.